Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.52 |
| ▸ | MPO | P05164 | 3/20 | 0.51 |
| ▸ | LIPC | P11150 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853391 | 1.00 | TAS2R14 (0.52) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL22853381 | 0.88 | CFTR (0.47) | TAS2R14MPODHODH | |
| SCHEMBL30294664 | 0.85 | TAS2R14 (0.55) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL22853095 | 0.84 | TAS2R14 (0.53) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL30294773 | 0.83 | TAS2R14 (0.59) | TAS2R14MPOAKR1C3AKR1C2SORT1 | |
| SCHEMBL22853132 | 0.83 | TAS2R14 (0.59) | TAS2R14MPOAKR1C3AKR1C2SORT1 | |
| SCHEMBL29383283 | 0.83 | MPO (0.61) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL22833319 | 0.83 | MPO (0.61) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL22852835 | 0.81 | TAS2R14 (0.62) | TAS2R14MPOLIPCLIPGAKR1C3 | |
| SCHEMBL30294708 | 0.81 | TAS2R14 (0.62) | TAS2R14MPOLIPCLIPGAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | TAS2R14 1406/4885MPO 3074/4885LIPC 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.